
VP of Sales, @Vesalio #vascularsurgery #interventionalradiology #cardiotwitter #vasctwitter #stroke #aneurysm #thrombus
Cleveland, OH USA
Joined October 2023
- Tweets60
- Following855
- Followers154
- Likes223
Bob Bushok retweeted
Thanks to everyone who stopped by the Vesalio booth at #TCT2026. It was exciting to see the international and U.S. communities come together to put evidence and experience to work. We enjoyed sharing #enVast and the NATURE RCT findings on large thrombus burden. #DoTheDropZone
Bob Bushok retweeted
Is it time to rethink your first move in primary PCI? Visit us at #TCT2026 & learn about the NATURE RCT showing a 26% smaller infarct size in the #enVast arm, compared to conventional PCI in #STEMI patients presenting w/ LTB.
#DoTheDropZone
Ref jacc.org/doi/10.1016/j.jacc.…
Bob Bushok retweeted
How are you treating patients w/ large thrombus burden (LTB)? Visit us at TCT & learn about the NATURE randomized controlled trial showing a 26% smaller infarct size in the #enVast arm than in conventional PCI in #STEMI patients presenting w/ #LTB.
Ref doi.org/10.1016/j.jacc.2026.…
Bob Bushok retweeted
We welcome Daniel Davis! He’s joining Vesalio’s Board of Directors and serving as Advisor to our CEO, Steve Rybka.
25+ years building thrombectomy businesses at Penumbra and Imperative Care. Read the full release: vesalio.com/vesalio-appoints…
#LeaveNoClotBehind
Bob Bushok retweeted
Coverage from @WebullGlobal on the #NATUREStudy following its presentation at #ESC2026.
➡️webull.com/news/154861817758…
enVast is FDA-cleared & CE-marked. See vesalio.com/envast-ifu-fda or vesalio.com/envast-ifu-ce depending on your region, for indications, safety & warnings.
Bob Bushok retweeted
Dr. Giuseppe Biondi Zoccai takes a closer look at the #NATUREStudy & the results presented at #ESC2026. @gbiondizoccai
enVast is FDA-cleared & CE-marked. See vesalio.com/envast-ifu-fda or vesalio.com/envast-ifu-ce depending on your region, for indications, safety & warnings.
This quoted post is unavailable.
Bob Bushok retweeted
Professor Marco Valgimigli discusses the NATURE study following presentation of the results at #ESC2026 in this interview with Dr. Mirvat Alasnag, Dr. @SimoneBiscaglia and Dr. Jasper Boeddinghaus.
#NATUREStudy @vlgmrc @mirvatalasnag
Link to discussion: youtube.com/watch?v=2zAIJ5Sv…
Bob Bushok retweeted
This JACC editorial by Ziad A. Ali, MD discusses the NATURE study post-#ESC2026. #NATUREStudy @ziadalinyc
jacc.org/doi/10.1016/j.jacc.…
Bob Bushok retweeted
Cardiac Interventions Today takes a closer look at the NATURE study and the results presented at #ESC2026. #NATUREStudy
enVast is FDA-cleared and CE-marked. See vesalio.com/envast-ifu-fda or vesalio.com/envast-ifu-ce depending on your region, for indications, safety and warnings.
Vesalio’s enVast for Mechanical Thrombectomy in Large-Thrombus STEMI Studied in NATURE | @VESALIOcom citoday.com/news/vesalios-en…
Bob Bushok retweeted
Dr. Maikel Valdes Garcia disusses NATURE & its implications for coronary thrombectomy. #NATUREStudy Professor Marco Valgimigli @vlgmrc
linkedin.com/posts/maikel-va…
Bob Bushok retweeted
Dr @vlgmrc and Dr @CMichaelGibson discuss the NATURE study and the results presented at #ESC2026. #NATUREStudy
enVast is FDA-cleared & CE-marked. See vesalio.com/envast-ifu-fda or
vesalio.com/envast-ifu-ce depending on your region, for indications, safety information & warnings.
Dr. Marco Valgimigli and Dr. C. Michael Gibson discuss the NATURE trial: enVast thrombectomy as an adjunctive reperfusion strategy reduced the infarct size by 25% compared to conventional PCI in STEMI patients with large thrombus burden. Watch video here: clinicaltrialresults.org/wp-…
Bob Bushok retweeted
Dr. Marco Valgimigli and Dr. C. Michael Gibson discuss the NATURE trial: enVast thrombectomy as an adjunctive reperfusion strategy reduced the infarct size by 25% compared to conventional PCI in STEMI patients with large thrombus burden. Watch video here: clinicaltrialresults.org/wp-…
Bob Bushok retweeted
Great week at #iCureStroke2026/Istanbul!
Drs Ribó, @ArsidaBajrami & Jesser shared strong #NeVa/#NeVaNET cases to a packed room. Thanks Prof Geyik, @RaulNogueiraMD, @DekonGroup & faculty for a rich, case-based symposium. Partner with us.
#DoTheDropZone #LeaveNoClotBehind @DTangun
Bob Bushok retweeted
The Vesalio team is at #SNIS2026 sharing latest updates on #NeVaVS - the only FDA-approved device for the treatment of cerebral #vasospasm due to #aSAH. 🧠
🗓️ Please visit us at Booth #404 or 📲 DM @bobbushok to connect!
Hope to see you soon!
@SNISinfo
Bob Bushok retweeted
Congrats to Dr Paparoni, Dr Lezzi, Dr Remigis & ASL Teramo's Emodinamica team on this #enVast case.
enVast is FDA-cleared and CE-marked. See vesalio.com/envast-ifu-fda or vesalio.com/envast-ifu-ce depending on your region, for indications, safety & warnings.
➡️linkedin.com/posts/hernan-ve…
Bob Bushok retweeted
Single pass. TIMI 3 flow. Zero debris. 🎉 Nice work Dr Arif Al Nooryani & Al Qassimi Hospital team with #enVast™ in a challenging mid-LAD STEMI case. #LeaveNoClotBehind
FDA cleared & CE marked. See vesalio.com/envast-ifu/for indications, safety & warnings
linkedin.com/posts/kawtar-gh…
Bob Bushok retweeted
#NeVaNET 4.0: 94% first-pass TICI 2c/3! @drpaulbhogal (UK) & Dr @VladimirKZagreb (Croatia) share early results (20 patients) at @brainconferenc1 ‘24.
Next-gen #stroke #thrombectomy tech—game-changer? Watch: tiny.cc/7i9d001
#FirstPassSuccess
tiny.cc/7i9d001
Bob Bushok retweeted
How do you reduce overnight thrombolysis or open surgery when a hard, distal clot is below the knee or in the arm? Learn how #pVasc uses a streamlined approach and the lowest profile delivery to remove clot at #ISET2025.
Hope to see you there!
#DoTheDropZone @ISETNews
Bob Bushok retweeted
💥Got a tough distal clot below the knee or in the arm? Discover a cutting-edge approach to removing clots efficiently with our low-profile #pVasc device! Learn all about our innovative solutions at #VEITH24. More Info, DM @bobbushok
@VEITHsymposium #PeripheralArterialDisease







